Yi Hu
Impact in
- Oncology top 0.2%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Inflammatory Biomarkers in Disease Prognosis
- Pulmonary and Respiratory Medicine top 0.5%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Brain Metastases and Treatment
Papers in
- Oncology 120
- Cancer Immunotherapy and Biomarkers 60
- Lung Cancer Research Studies 31
- Inflammatory Biomarkers in Disease Prognosis 13
-
- Lung Cancer Treatments and Mutations 54
- Lung Cancer Diagnosis and Treatment 16
- Co-authors
- Yangzhe Wu (9 shared papers)Haitao Tao (40 shared papers)Jinliang Wang (26 shared papers)Shunchang Jiao (19 shared papers)Sujie Zhang (14 shared papers)Yijia Li (4 shared papers)Yixue Xue (11 shared papers)Zhibo Zhang (13 shared papers)
- Journals
- Frontiers in Oncology (18 papers)Translational Lung Cancer Research (11 papers)Journal of Thoracic Oncology (8 papers)Cancer Medicine (7 papers)Frontiers in Immunology (7 papers)
- Partner nations
- ChinaUnited StatesHong Kong
In The Last Decade
Yi Hu
293 papers receiving 11.9k citations
Yi Hu's Hit Papers
Peers
Comparison fields: 5 of 115
- Oncology 6.5k
- Pulmonary and Respiratory Medicine 2.6k
- Cancer Research 855
- Immunology 556
- Hepatology 180
Countries citing papers authored by Yi Hu
This map shows the geographic impact of Yi Hu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yi Hu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yi Hu more than expected).
Fields of papers citing papers by Yi Hu
This network shows the impact of papers produced by Yi Hu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yi Hu. The network helps show where Yi Hu may publish in the future.
Co-authors
The 25 scholars most cited alongside Yi Hu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 311 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial Hit paper breakdown → | 2019 | 2712 |
| 2 | Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial Hit paper breakdown → | 2019 | 1737 |
| 3 | Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial Hit paper breakdown → | 2020 | 522 |
| 4 | Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study Hit paper breakdown → | 2020 | 490 |
| 5 | Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial Hit paper breakdown → | 2020 | 368 |
| 6 | Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer Hit paper breakdown → | 2021 | 349 |
| 7 | Programmed Cell Death Tunes Tumor Immunity Hit paper breakdown → | 2022 | 255 |
| 8 | γδ T cells: origin and fate, subsets, diseases and immunotherapy Hit paper breakdown → | 2023 | 239 |
| 9 | 2018 | 186 | |
| 10 | 2019 | 122 | |
| 11 | Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials Hit paper breakdown → | 2023 | 122 |
| 12 | 2015 | 117 | |
| 13 | 2019 | 114 | |
| 14 | 2020 | 111 | |
| 15 | 2015 | 105 | |
| 16 | 2018 | 101 | |
| 17 | 2021 | 101 | |
| 18 | 2019 | 97 | |
| 19 | 2019 | 91 | |
| 20 | 2020 | 72 |
About Yi Hu
Yi Hu is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Immunology and Molecular Biology, having authored 311 papers that have together received 12.1k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (60 papers), Lung Cancer Treatments and Mutations (54 papers), Lung Cancer Research Studies (31 papers), Lung Cancer Diagnosis and Treatment (16 papers), Esophageal Cancer Research and Treatment (14 papers), Inflammatory Biomarkers in Disease Prognosis (13 papers), MicroRNA in disease regulation (9 papers) and Hepatocellular Carcinoma Treatment and Prognosis (8 papers). The work is most often cited by research in Oncology (6.5k citations), Pulmonary and Respiratory Medicine (2.6k citations), Cancer Research (855 citations), Immunology (556 citations) and Hepatology (180 citations). Yi Hu has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Yangzhe Wu, Haitao Tao, Jinliang Wang, Shunchang Jiao, Sujie Zhang, Yijia Li, Yixue Xue, Zhibo Zhang, Dan Chen and Jing Liu. Their work appears in journals such as Frontiers in Oncology, Translational Lung Cancer Research, Journal of Thoracic Oncology, Cancer Medicine and Frontiers in Immunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.